Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

Particle-engineering technologies, such as crystal design for crystallization and producting cocrystals, particle-size reduction, and amorphous solid dispersions, help to optimize delivery of a drug.

Seeking Solutions in Solid-State Chemistry

Policymakers must balance fundamental issues involving access to medicines and pricing.

Weighing Access and Affordability

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Manufacturing and in-depth characterization provide basis for demonstrating product equivalence.

Product Analysis Key to Biosimilar Development

Sean Milmo is a freelance writer based in Essex, UK.

The European Medicines Agency has added granularity to its biosimilars approval pathway by releasing a guideline on biosimilar monoclonal antibodies (mAbs).

EU Sets Guidelines for Biosimilar Monoclonal Antibodies

New systems that combine Raman spectroscopy with automated imaging support the efficient gathering of such data, including information concerning size and shape distributions for individual components within a formulation.

Combining Spectroscopy with Automated Imaging: A New Analytical Solution to Meet Regulatory Requirements for Inhaled Products

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

AET BioTech and BioXpress Therapeutics have entered into an agreement to codevelop a biosimilar version of Abbott's tumor necrosis factor inhibitor monoclonal antibody adalimumab.

AET BioTech and BioXpress Therapeutics to Codevelop Adalimumab Biosimilar

Potency is a required measurement to determine the amount of active ingredient contained in a preclinical dose formulation. Assessing potency ensures that the test system receives the appropriate amount of active ingredient based on predetermined specifications.

Determining Potency of Preclinical Dose Formulations

Fluid-Bag Ltd provides comprehensive 900 and 1000 litre flexible IBC systems for liquid and semi-solid products, including filling and discharging equipment. The GMP compliant container system is designed to guarantee uniform liquid, maximise payload and minimise discharge residue (0.5% residue).

FLUID-BAG MULTI &#151; superior logistics for liquid and semi-solid pharmaceutical products

The long-awaited patent cliff that has loomed in the pharmaceutical industry for years has arrived in earnest in 2012, with more than $40 billion in 2011 brand sales facing loss of exclusivity.